Key result
The Ingelvac PRRS MLV vaccine provided incomplete cross-protection against newly emerging heterologous NADC30-like PRRSVs, protecting against FJZ03 but offering limited protection against FJWQ16.
Why the study?
The study was conducted to determine the cross-protection of Ingelvac PRRS MLV against challenge with new lineage 1 PRRSV emerging in China in pigs.
Does the Ingelvac PRRS MLV vaccine provide cross-protection against challenge with Chinese lineage 1 PRRSVs in pigs?
RCT (n=25)
Blinded for pathology evaluation
Randomly divided into 5 groups
No
Does the Ingelvac PRRS MLV vaccine provide cross-protection against challenge with Chinese lineage 1 PRRSVs in pigs?
The PRRSV-MLV vaccine provides incomplete and strain-dependent protection against new lineage 1 PRRSVs in pigs.
Warrants monitoring vaccine performance vs emerging strains; leaves open need for broader cross-protection.
The objective of the present study was to determine the cross-protection of Ingelvac PRRS MLV against challenge with the new lineage 1 PRRSV emerged in China in pigs. Two lineage 1 PRRSV strains (FJZ03 and FJWQ16 originated from recombination event between NADC30 and JXA1-like strain). We found that pigs vaccinated with the vaccine were protected against challenge with the FJZ03 as shown by fewer days of clinical fever, reduced lung pathology scores, lower PRRS virus load in the blood and developed broadly neutralizing antibodies with high titers to FJZ03. In contrast, vaccine provided limited protection against challenge with FJWQ16 with higher fever, lower antibody titers, lower neutralizing antibodies and higher viral loads in blood. These results demonstrate PRRSV-MLV provides incomplete protection against new lineage 1 PRRSVs.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2019) conducted an RCT in Porcine reproductive and respiratory syndrome (PRRS) (n=25). Ingelvac PRRS MLV vaccine vs. PBS (mock vaccination) was evaluated on Macroscopic lung lesion score (MLV + FJWQ16 vs FJWQ16). The Ingelvac PRRS MLV vaccine provided incomplete cross-protection against newly emerging heterologous NADC30-like PRRSVs, protecting against FJZ03 but offering limited protection against FJWQ16.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: